Literature DB >> 22617361

Cyclic vomiting syndrome in 28 patients: demographics, features and outcomes.

Lennard Y Lee1, Laura Abbott, Simon Moodie, Simon Anderson.   

Abstract

INTRODUCTION: Cyclic vomiting syndrome (CVS) is a condition characterized by recurrent, stereotyped, attacks of intense nausea and intractable vomiting with no identifiable cause. The diagnosis is made according to the Rome III criteria; however, the condition remains a heterogenous group of symptoms and few studies have analysed patient-reported features in detail. Tricyclic antidepressants may benefit some patients, but there are no data on the long-term outcomes of this condition.
METHODS: This is a retrospective cohort study of all patients treated at two London teaching hospitals between 1994 and 2011. Information was obtained by means of inpatient case notes, clinic letters and telephone interviews using a standardized questionnaire.
RESULTS: Twenty-eight patients were identified, 17 with adult-onset CVS and 11 with childhood-onset CVS. In the adult-onset CVS cohort, the average age of onset was 30 years; the prevalence of headache was 57.1% and anxiety/depression 21.7%. Vomiting attacks occurred on average 10 times a year with a mean duration of 55.3 h. In the childhood-onset CVS cohort, the average age of onset was 5 years and the prevalence of headaches was 44.4%. Vomiting attacks occurred on average 25.5 times a year with a mean duration of 54.5 h. During acute attacks, patients rated morphine-based medications as the most efficacious. Overall, 65.4% of our patients were not treated with long-term prophylactic medications and, of these, 42.1% felt that their symptoms had improved and 26.3% reported complete resolution.
CONCLUSION: CVS is a debilitating illness with frequent attacks of prolonged duration. There is a high association with anxiety/depression as well as headaches. Antimigraine medication, β-blockers and antiepileptic treatment may be successful at attenuating attacks; however, in this long-term study, the prognosis of patients not treated with these medications was also good. Overall, 61.9% of patients showed a gradual improvement in symptoms and 23.8% had complete resolution after a mean of 7 years.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617361     DOI: 10.1097/MEG.0b013e328354fc83

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Cyclical vomiting syndrome: Recognition, assessment and management.

Authors:  Michelle Ln Tan; Maria Janelle Liwanag; Seng Hock Quak
Journal:  World J Clin Pediatr       Date:  2014-08-08

2.  Symptomatic management of a child with cyclic vomiting syndrome.

Authors:  Shanthan Mettu; Dwitha Animireddy; Pratej Kiran Kanumuri; Radhika Muppa
Journal:  BMJ Case Rep       Date:  2016-08-16

Review 3.  Recurrent Gastrointestinal Disturbance: Abdominal Migraine and Cyclic Vomiting Syndrome.

Authors:  Samantha Irwin; Rebecca Barmherzig; Amy Gelfand
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

Review 4.  The Role of the Endocannabinoid System in the Brain-Gut Axis.

Authors:  Keith A Sharkey; John W Wiley
Journal:  Gastroenterology       Date:  2016-04-29       Impact factor: 22.682

5.  Depression, young age, chronic marijuana use, and interepisodic symptoms predict psychological distress in patients with cyclic vomiting syndrome.

Authors:  Tatyana Taranukha; Vishnu Charan Suresh Kumar; Alex Seamon; Natasha Sahr; Aniko Szabo; Thangam Venkatesan
Journal:  Neurogastroenterol Motil       Date:  2017-11-20       Impact factor: 3.598

6.  The efficacy and duration of treatment with propranolol in children with cyclic vomiting syndrome in southern Iran.

Authors:  Mahmoud Haghighat; Hajar Memari; Naser Honar; Seyed Mohsen Dehghani; Mohammad-Hadi Imanieh; Seyed-Javad Injoo; Hazhir Javaherizadeh
Journal:  Prz Gastroenterol       Date:  2017-12-14

Review 7.  Cyclic Vomiting Syndrome: A Functional Disorder.

Authors:  Ajay Kaul; Kanwar K Kaul
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2015-12-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.